Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
DENO
- Cancer Type
- Genitourinary, Prostate
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
ODB Limited Use denosumab (Wyost™ brand) - For the treatment of bony metastases for patients with hormone refractory prostate cancer as determined by an elevated PSA level, or evidence of progressive bony disease, despite castrate serum testosterone levels or having undergone orchidectomy, based on criteria New Drug Funding Program Denosumab (Biosimilar) - Hormone Refractory Prostate Cancer
- Drugs Used
- denosumab
Regimen Monograph
Sep 2024
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
